Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions

Objective: This study aimed to evaluate the risk of incident diabetes between people who used lovastatin and red yeast rice (RYR) prescriptions. Methods: A retrospective cohort study was performed to analyze the real-world database of Taiwan's National Health Insurance. We identified the RYR co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes, metabolic syndrome and obesity metabolic syndrome and obesity, 2020-01, Vol.13, p.89
Hauptverfasser: Sung, Li-Chin, Lin, Chao-Shun, Lia, Chien-Chang, Yeh, Chun-Chieh, Shih, Chun-Chuan, Chang, Yi-Cheng, Chen, Ta-Liang, Lin, Jui-An
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 89
container_title Diabetes, metabolic syndrome and obesity
container_volume 13
creator Sung, Li-Chin
Lin, Chao-Shun
Lia, Chien-Chang
Yeh, Chun-Chieh
Shih, Chun-Chuan
Chang, Yi-Cheng
Chen, Ta-Liang
Lin, Jui-An
description Objective: This study aimed to evaluate the risk of incident diabetes between people who used lovastatin and red yeast rice (RYR) prescriptions. Methods: A retrospective cohort study was performed to analyze the real-world database of Taiwan's National Health Insurance. We identified the RYR cohort, which included 34,504 persons age 20 years or older who began their use of a RYR prescription in 2010-2014. A comparison cohort of 34,504 adults beginning the use of lovastatin was selected from the same dataset, which was matched by age and sex. Both cohorts had no diabetes before the use of the medications. Events of incident diabetes in 2000-2015 were ascertained from medical claims. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of incident diabetes associated with the use of RYR prescriptions were calculated. Results: The incidences of diabetes for the RYR cohort and the lovastatin cohort were 1.01 and 2.59 per 100 person-years, respectively (P < 0.0001). Compared with the lovastatin cohort, the adjusted HR of incident diabetes was 0.46 (95% CI 0.43-0.50) for people who used RYR prescriptions. The association between reduced incident diabetes and use of RYR prescriptions was significant in various subgroups. There was a dose-response relationship between RYR prescriptions and the reduced risk of incident diabetes. Conclusion: We raised the possibility that people who used RYR prescriptions may have a lower risk of incident diabetes compared with the lovastatin cohort. Keywords: diabetes, lovastatin, red yeast rice, risk
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_healthsolutions_A614152397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A614152397</galeid><sourcerecordid>A614152397</sourcerecordid><originalsourceid>FETCH-gale_healthsolutions_A6141523973</originalsourceid><addsrcrecordid>eNqNjMsKwjAQRYMoWNR_mJW7Qlsf0aVPFFxIUcSVxHbapoZEOrH-vlFcuHQ2M5x75jaYF4Z84vMg4M2fu816RGXwHh4Mo8hj5aoW6iGs1DnEkm5gMtjqRKaoLSyluKJFgjnaJ6KGvRNdQHAqDBwJU9iZWpB9_4PQKcQOndERV5Yg7CukpJJ3K42mLmtlQhH2vrvD-uvVYbHxc6HwUqBQtiCjHh_5MhuHw3AUDaZ88Lf4AhUCTB4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis (Open Access)</source><source>Dove Press Free</source><source>Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB Electronic Journals Library</source><creator>Sung, Li-Chin ; Lin, Chao-Shun ; Lia, Chien-Chang ; Yeh, Chun-Chieh ; Shih, Chun-Chuan ; Chang, Yi-Cheng ; Chen, Ta-Liang ; Lin, Jui-An</creator><creatorcontrib>Sung, Li-Chin ; Lin, Chao-Shun ; Lia, Chien-Chang ; Yeh, Chun-Chieh ; Shih, Chun-Chuan ; Chang, Yi-Cheng ; Chen, Ta-Liang ; Lin, Jui-An</creatorcontrib><description>Objective: This study aimed to evaluate the risk of incident diabetes between people who used lovastatin and red yeast rice (RYR) prescriptions. Methods: A retrospective cohort study was performed to analyze the real-world database of Taiwan's National Health Insurance. We identified the RYR cohort, which included 34,504 persons age 20 years or older who began their use of a RYR prescription in 2010-2014. A comparison cohort of 34,504 adults beginning the use of lovastatin was selected from the same dataset, which was matched by age and sex. Both cohorts had no diabetes before the use of the medications. Events of incident diabetes in 2000-2015 were ascertained from medical claims. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of incident diabetes associated with the use of RYR prescriptions were calculated. Results: The incidences of diabetes for the RYR cohort and the lovastatin cohort were 1.01 and 2.59 per 100 person-years, respectively (P &lt; 0.0001). Compared with the lovastatin cohort, the adjusted HR of incident diabetes was 0.46 (95% CI 0.43-0.50) for people who used RYR prescriptions. The association between reduced incident diabetes and use of RYR prescriptions was significant in various subgroups. There was a dose-response relationship between RYR prescriptions and the reduced risk of incident diabetes. Conclusion: We raised the possibility that people who used RYR prescriptions may have a lower risk of incident diabetes compared with the lovastatin cohort. Keywords: diabetes, lovastatin, red yeast rice, risk</description><identifier>ISSN: 1178-7007</identifier><identifier>EISSN: 1178-7007</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Antilipemic agents ; Insurance ; Lovastatin ; National health insurance</subject><ispartof>Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.89</ispartof><rights>COPYRIGHT 2020 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids></links><search><creatorcontrib>Sung, Li-Chin</creatorcontrib><creatorcontrib>Lin, Chao-Shun</creatorcontrib><creatorcontrib>Lia, Chien-Chang</creatorcontrib><creatorcontrib>Yeh, Chun-Chieh</creatorcontrib><creatorcontrib>Shih, Chun-Chuan</creatorcontrib><creatorcontrib>Chang, Yi-Cheng</creatorcontrib><creatorcontrib>Chen, Ta-Liang</creatorcontrib><creatorcontrib>Lin, Jui-An</creatorcontrib><title>Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions</title><title>Diabetes, metabolic syndrome and obesity</title><description>Objective: This study aimed to evaluate the risk of incident diabetes between people who used lovastatin and red yeast rice (RYR) prescriptions. Methods: A retrospective cohort study was performed to analyze the real-world database of Taiwan's National Health Insurance. We identified the RYR cohort, which included 34,504 persons age 20 years or older who began their use of a RYR prescription in 2010-2014. A comparison cohort of 34,504 adults beginning the use of lovastatin was selected from the same dataset, which was matched by age and sex. Both cohorts had no diabetes before the use of the medications. Events of incident diabetes in 2000-2015 were ascertained from medical claims. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of incident diabetes associated with the use of RYR prescriptions were calculated. Results: The incidences of diabetes for the RYR cohort and the lovastatin cohort were 1.01 and 2.59 per 100 person-years, respectively (P &lt; 0.0001). Compared with the lovastatin cohort, the adjusted HR of incident diabetes was 0.46 (95% CI 0.43-0.50) for people who used RYR prescriptions. The association between reduced incident diabetes and use of RYR prescriptions was significant in various subgroups. There was a dose-response relationship between RYR prescriptions and the reduced risk of incident diabetes. Conclusion: We raised the possibility that people who used RYR prescriptions may have a lower risk of incident diabetes compared with the lovastatin cohort. Keywords: diabetes, lovastatin, red yeast rice, risk</description><subject>Antilipemic agents</subject><subject>Insurance</subject><subject>Lovastatin</subject><subject>National health insurance</subject><issn>1178-7007</issn><issn>1178-7007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNjMsKwjAQRYMoWNR_mJW7Qlsf0aVPFFxIUcSVxHbapoZEOrH-vlFcuHQ2M5x75jaYF4Z84vMg4M2fu816RGXwHh4Mo8hj5aoW6iGs1DnEkm5gMtjqRKaoLSyluKJFgjnaJ6KGvRNdQHAqDBwJU9iZWpB9_4PQKcQOndERV5Yg7CukpJJ3K42mLmtlQhH2vrvD-uvVYbHxc6HwUqBQtiCjHh_5MhuHw3AUDaZ88Lf4AhUCTB4</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Sung, Li-Chin</creator><creator>Lin, Chao-Shun</creator><creator>Lia, Chien-Chang</creator><creator>Yeh, Chun-Chieh</creator><creator>Shih, Chun-Chuan</creator><creator>Chang, Yi-Cheng</creator><creator>Chen, Ta-Liang</creator><creator>Lin, Jui-An</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20200101</creationdate><title>Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions</title><author>Sung, Li-Chin ; Lin, Chao-Shun ; Lia, Chien-Chang ; Yeh, Chun-Chieh ; Shih, Chun-Chuan ; Chang, Yi-Cheng ; Chen, Ta-Liang ; Lin, Jui-An</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_healthsolutions_A6141523973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antilipemic agents</topic><topic>Insurance</topic><topic>Lovastatin</topic><topic>National health insurance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sung, Li-Chin</creatorcontrib><creatorcontrib>Lin, Chao-Shun</creatorcontrib><creatorcontrib>Lia, Chien-Chang</creatorcontrib><creatorcontrib>Yeh, Chun-Chieh</creatorcontrib><creatorcontrib>Shih, Chun-Chuan</creatorcontrib><creatorcontrib>Chang, Yi-Cheng</creatorcontrib><creatorcontrib>Chen, Ta-Liang</creatorcontrib><creatorcontrib>Lin, Jui-An</creatorcontrib><jtitle>Diabetes, metabolic syndrome and obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sung, Li-Chin</au><au>Lin, Chao-Shun</au><au>Lia, Chien-Chang</au><au>Yeh, Chun-Chieh</au><au>Shih, Chun-Chuan</au><au>Chang, Yi-Cheng</au><au>Chen, Ta-Liang</au><au>Lin, Jui-An</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions</atitle><jtitle>Diabetes, metabolic syndrome and obesity</jtitle><date>2020-01-01</date><risdate>2020</risdate><volume>13</volume><spage>89</spage><pages>89-</pages><issn>1178-7007</issn><eissn>1178-7007</eissn><abstract>Objective: This study aimed to evaluate the risk of incident diabetes between people who used lovastatin and red yeast rice (RYR) prescriptions. Methods: A retrospective cohort study was performed to analyze the real-world database of Taiwan's National Health Insurance. We identified the RYR cohort, which included 34,504 persons age 20 years or older who began their use of a RYR prescription in 2010-2014. A comparison cohort of 34,504 adults beginning the use of lovastatin was selected from the same dataset, which was matched by age and sex. Both cohorts had no diabetes before the use of the medications. Events of incident diabetes in 2000-2015 were ascertained from medical claims. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of incident diabetes associated with the use of RYR prescriptions were calculated. Results: The incidences of diabetes for the RYR cohort and the lovastatin cohort were 1.01 and 2.59 per 100 person-years, respectively (P &lt; 0.0001). Compared with the lovastatin cohort, the adjusted HR of incident diabetes was 0.46 (95% CI 0.43-0.50) for people who used RYR prescriptions. The association between reduced incident diabetes and use of RYR prescriptions was significant in various subgroups. There was a dose-response relationship between RYR prescriptions and the reduced risk of incident diabetes. Conclusion: We raised the possibility that people who used RYR prescriptions may have a lower risk of incident diabetes compared with the lovastatin cohort. Keywords: diabetes, lovastatin, red yeast rice, risk</abstract><pub>Dove Medical Press Limited</pub></addata></record>
fulltext fulltext
identifier ISSN: 1178-7007
ispartof Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.89
issn 1178-7007
1178-7007
language eng
recordid cdi_gale_healthsolutions_A614152397
source Open Access: PubMed Central; Taylor & Francis (Open Access); Dove Press Free; Directory of Open Access Journals; PubMed Central Open Access; EZB Electronic Journals Library
subjects Antilipemic agents
Insurance
Lovastatin
National health insurance
title Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T19%3A10%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20Risk%20of%20Incident%20Diabetes%20Between%20Patients%20Who%20Used%20Lovastatin%20and%20Red%20Yeast%20Rice%20Prescriptions&rft.jtitle=Diabetes,%20metabolic%20syndrome%20and%20obesity&rft.au=Sung,%20Li-Chin&rft.date=2020-01-01&rft.volume=13&rft.spage=89&rft.pages=89-&rft.issn=1178-7007&rft.eissn=1178-7007&rft_id=info:doi/&rft_dat=%3Cgale%3EA614152397%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A614152397&rfr_iscdi=true